MolPharm Over 1500 Individual Drug Articles!

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on February 7, 2007; DOI: 10.1124/mol.106.032722


0026-895X/07/7105-1349-1359$20.00
Mol Pharmacol 71:1349-1359, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.032722v1
71/5/1349    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Related articles in MolPharm
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lane, J. R.
Right arrow Articles by Milligan, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lane, J. R.
Right arrow Articles by Milligan, G.

Protean Agonism at the Dopamine D2 Receptor: (S)-3-(3-Hydroxyphenyl)-N-propylpiperidine Is an Agonist for Activation of Go1 but an Antagonist/Inverse Agonist for Gi1,Gi2, and Gi3

J. Robert Lane, Ben Powney, Alan Wise, Steven Rees, and Graeme Milligan

Molecular Pharmacology Group, Division of Biochemistry and Molecular Biology, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom (J.R.L., G.M.); and Screening & Compound Profiling, GlaxoSmithKline Research & Development, Harlow, Essex, United Kingdom (A.W., S.R., B.P.)

A range of ligands displayed agonism at the long isoform of the human dopamine D2 receptor, whether using receptor-G protein fusions or membranes of cells in which pertussis toxin-resistant mutants of individual G{alpha}i-family G proteins could be expressed in an inducible fashion. Varying degrees of efficacy were observed for individual ligands as monitored by their capacity to load [35S]GTP{gamma}S onto each of G{alpha}i1,G{alpha}i2,G{alpha}i3, and G{alpha}o1. By contrast, (S)-(–)-3-(3-hydroxyphenyl)-N-propylpiperidine was a partial agonist when G{alpha}o1 was the target G protein but an antagonist/inverse agonist at G{alpha}i1,G{alpha}i2, and G{alpha}i3. In ligand binding assays, dopamine identified both high- and low-affinity states at each of the dopamine D2 receptor-G protein fusion proteins, and the high-affinity state was eliminated by guanine nucleotide. (S)-(–)-3-(3-Hydroxyphenyl)-N-propylpiperidine bound to an apparent single state of the constructs in which the D2 receptor was fused to G{alpha}i1,G{alpha}i2, or G{alpha}i3. However, it bound to distinct high- and low-affinity states of the D2 receptor-G{alpha}o1 fusion, with the high-affinity state being eliminated by guanine nucleotide. Likewise, although dopamine identified guanine nucleotide-sensitive high-affinity states of the D2 receptor when expression of pertussis toxin-resistant forms of each of G{alpha}i1, G{alpha}i2, G{alpha}i3, and G{alpha}o1 was induced, (S)-(–)-3-(3-hydroxyphenyl)-N-propylpiperidine identified a high-affinity site only in the presence of G{alpha}o1. p-Tyramine displayed a protean ligand profile similar to that of (S)-(–)-3-(3-hydroxyphenyl)-N-propylpiperidine but with lower potency. These results demonstrate (S)-(–)-3-(3-hydroxyphenyl)-N-propylpiperidine to be a protean agonist at the D2 receptor and may explain in vivo actions of this ligand.


Received November 15, 2006; accepted February 7, 2007

Address correspondence to: Dr. G. Milligan, Davidson Building, University of Glasgow, Glasgow G12 8QQ, Scotland, U.K. E-mail: g.milligan{at}bio.gla.ac.uk


Related articles in MolPharm:

Missing Links: Mechanisms of Protean Agonism
Richard R. Neubig
MolPharm 2007 71: 1200-1202. [Abstract] [Full Text]  



This article has been cited by other articles:


Home page
FASEB J.Home page
J. R. Lane, D. Henderson, B. Powney, A. Wise, S. Rees, D. Daniels, C. Plumpton, I. Kinghorn, and G. Milligan
Antibodies that identify only the active conformation of Gi family G protein {alpha} subunits
FASEB J, June 1, 2008; 22(6): 1924 - 1932.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Canals and G. Milligan
Constitutive Activity of the Cannabinoid CB1 Receptor Regulates the Function of Co-expressed Mu Opioid Receptors
J. Biol. Chem., April 25, 2008; 283(17): 11424 - 11434.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. R. Lane, B. Powney, A. Wise, S. Rees, and G. Milligan
G Protein Coupling and Ligand Selectivity of the D2L and D3 Dopamine Receptors
J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 319 - 330.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. J. Millan, C. M. la Cour, F. Novi, R. Maggio, V. Audinot, A. Newman-Tancredi, D. Cussac, V. Pasteau, J.-A. Boutin, T. Dubuffet, et al.
S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], A Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: I. Receptor-Binding Profile and Functional Actions at G-Protein-Coupled Receptors
J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 587 - 599.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics